GT Biopharma (GTBP) Institutional Ownership $2.39 +0.06 (+2.58%) Closing price 01/17/2025 03:59 PM EasternExtended Trading$2.28 -0.11 (-4.60%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for GT Biopharma (NASDAQ:GTBP)CurrentInstitutional OwnershipPercentage8.15%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$4.84MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$326.26K Get GTBP Insider Trade Alerts Want to know when executives and insiders are buying or selling GT Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GTBP Institutional Buying and Selling by Quarter GT Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/8/2024DekaBank Deutsche Girozentrale978,358$2.77M0.0%-10.5%69.044% 6/4/2024DekaBank Deutsche Girozentrale1,093,645$47.45M0.1%N/A77.017% 8/2/2023Bank of Montreal Can596,240$262K0.0%N/A1.596% 1/23/2023Baskin Financial Services Inc.151,354$134K0.0%N/A0.466% 11/7/2022Virtu Financial LLC24,864$44K0.0%N/A0.076% 5/5/2022Russell Investments Group Ltd.11,007$31K0.0%N/A0.033% 5/2/2022Allspring Global Investments Holdings LLC25,782$74K0.0%N/A0.078% 4/20/2022Sigma Planning Corp21,400$62K0.0%N/A0.067% 2/14/2022Gordian Capital Singapore Pte Ltd35,000$107K0.1%N/A0.114% 2/9/2022Compagnie Lombard Odier SCmA30,000$92K0.0%+100.0%0.098% Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 2/4/2022Crumly & Associates Inc.32,163$85K0.0%N/A0.105% 2/3/2022Brighton Jones LLC11,288$34K0.0%N/A0.037% 1/31/2022Commonwealth Equity Services LLC11,052$33K0.0%N/A0.036% 11/16/2021Two Sigma Advisers LP51,100$344K0.0%+243.0%0.242% 11/16/2021Two Sigma Investments LP162,823$1.10M0.0%N/A0.771% 11/15/2021Marshall Wace LLP16,577$112K0.0%-35.7%0.078% 11/15/2021Franklin Resources Inc.28,500$192K0.0%N/A0.135% 11/12/2021Renaissance Technologies LLC84,700$571K0.0%N/A0.401% 11/12/2021Geode Capital Management LLC424,279$2.86M0.0%+22.4%2.008% 11/10/2021Goldman Sachs Group Inc.52,426$353K0.0%N/A0.248% 11/9/2021BlackRock Inc.1,155,228$7.79M0.0%-18.3%5.468% 11/8/2021State Board of Administration of Florida Retirement System18,224$123K0.0%N/A0.086% 11/8/2021Russell Investments Group Ltd.9,642$64K0.0%N/A0.046% 11/5/2021Welch Group LLC10,000$67K0.0%N/A0.047% 11/4/2021Deutsche Bank AG11,400$77K0.0%-25.7%0.054% 11/2/2021New York State Common Retirement Fund8,230$55K0.0%-59.7%0.039% 8/25/2021Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/17/2021Metropolitan Life Insurance Co NY8,782$136K0.0%N/A0.042% 8/17/2021MetLife Investment Management LLC11,471$178K0.0%N/A0.054% 8/17/2021Citadel Advisors LLC510,058$7.91M0.0%N/A2.414% 8/16/2021California State Teachers Retirement System32,878$510K0.0%N/A0.156% 8/16/2021Charles Schwab Investment Management Inc.57,993$899K0.0%N/A0.274% 8/16/2021State Street Corp374,704$5.81M0.0%N/A1.773% 8/16/2021Nuveen Asset Management LLC82,151$1.27M0.0%N/A0.389% 8/16/2021Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/13/2021Northern Trust Corp225,457$3.50M0.0%+555.6%1.067% 8/13/2021Geode Capital Management LLC346,606$5.37M0.0%+165.8%1.641% 8/13/2021Vanguard Group Inc.982,269$15.23M0.0%+267.0%4.649% 8/12/2021Legal & General Group Plc2,524$39K0.0%N/A0.012% 8/12/2021JPMorgan Chase & Co.9,155$142K0.0%N/A0.043% Ignore every stock… (Ad)Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%We put together this handy gold guide for you (no cost) so you know what to look for8/12/2021The Manufacturers Life Insurance Company13,758$213K0.0%N/A0.065% 8/11/2021Bank of New York Mellon Corp58,711$910K0.0%N/A0.278% 8/11/2021BlackRock Inc.1,413,391$21.91M0.0%N/A6.690% 8/11/2021Deutsche Bank AG15,349$237K0.0%N/A0.073% 8/10/2021Citigroup Inc.6,134$95K0.0%N/A0.029% 8/6/2021Ameritas Investment Partners Inc.1,870$29K0.0%N/A0.009% 8/5/2021Rhumbline Advisers18,634$289K0.0%N/A0.088% 8/2/2021New York State Common Retirement Fund20,400$316K0.0%N/A0.097% 8/2/2021Advisor Group Holdings Inc.2,943$45K0.0%+108.3%0.014% 7/31/2021Davy Global Fund Management Ltd35,113$544K0.1%+33.4%0.166% 7/15/2021Compagnie Lombard Odier SCmA15,000$233K0.0%N/A0.071% 7/6/2021 Silverleafe Capital Partners LLC104,000$1.61M0.6%N/A0.492% 5/19/2021Virtu Financial LLC22,741$156K0.0%N/A0.080% 5/19/2021Squarepoint Ops LLC16,543$113K0.0%N/A0.058% 5/18/2021Millennium Management LLC27,895$191K0.0%N/A0.098% 5/17/2021Royal Bank of Canada24,542$167K0.0%N/A0.086% 5/12/2021Northern Trust Corp34,387$235K0.0%N/A0.121% 5/12/2021Geode Capital Management LLC130,388$891K0.0%N/A0.459% 5/12/2021UBS Group AG3,918$27K0.0%N/A0.014% 5/11/2021Davy Global Fund Management Ltd26,321$180K0.0%N/A0.093% (Data available from 1/1/2016 forward) GTBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GTBP shares? During the previous two years, the following institutional investors and hedge funds held shares of GT Biopharma shares: DekaBank Deutsche Girozentrale ($2.77M), and Bank of Montreal Can ($262K), Baskin Financial Services Inc. ($134K).Learn more on GTBP's institutional investors. What percentage of GT Biopharma stock is owned by institutional investors? 8.15% of GT Biopharma stock is owned by institutional investors. Learn more on GTBP's institutional investor holdings. Which institutional investors have been buying GT Biopharma stock? The following institutional investors have purchased GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($1.09M), Bank of Montreal Can ($596.24K), and Baskin Financial Services Inc. ($151.35K). How much institutional buying is happening at GT Biopharma? Institutional investors have bought a total of 1,841,239 shares in the last 24 months. This purchase volume represents approximately $14.45M in transactions. Which GT Biopharma major shareholders have been selling company stock? The following institutional investors have sold GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($115.29K). How much institutional selling is happening at GT Biopharma? Institutional investors have sold a total of 115,287 shares in the last 24 months. This volume of shares sold represents approximately $326.26K in transactions. Related Companies NextCure Major Shareholders Cara Therapeutics Major Shareholders Tenax Therapeutics Major Shareholders Exicure Major Shareholders Athira Pharma Major Shareholders GeoVax Labs Major Shareholders MIRA Pharmaceuticals Major Shareholders Cyclo Therapeutics Major Shareholders Aprea Therapeutics Major Shareholders Bullfrog AI Major Shareholders This page (NASDAQ:GTBP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
